Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
Recent findings from the ASCO Gastrointestinal Cancers Symposium 2024 underscore the potential of innovative therapeutic combinations in enhancing outcomes for hepatocellular carcinoma patients, particularly those with unresectable or high-risk disease.
Oncology, Medical February 12th 2024
The New England Journal of Medicine
In this Phase 3 trial, resmetirom demonstrated a notable capacity to induce NASH resolution and improve liver fibrosis, offering hope for a therapeutic breakthrough in a field with limited treatment options. This study emphasizes the importance of advancing research in liver-directed therapies for NASH.
Gastroenterology February 12th 2024
Mayo Clinic
Explore innovative options for patients with pancreas, liver and biliary cancers at the Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2023.
Gastroenterology November 6th 2023
DocWire News
Based on the recent findings, would you consider tislelizumab over sorafenib tosylate as a potential first-line treatment for patients with unresectable HCC?
Oncology, Medical October 17th 2023
Discover how STRIDE is setting new benchmarks in the treatment of unresectable hepatocellular carcinoma, offering both improved survival rates and a tolerable safety profile.
Hepatology October 9th 2023
MDLinx
Explore the latest research illuminating the significant link between sugar-sweetened beverage consumption and liver disease risk in postmenopausal women—evidence that could inform your nutritional guidance to patients.
Family Medicine/General Practice September 25th 2023